Biotech funding tracker
Biotech funding news: 65 financing rounds from the last 60 days
Seed, venture, IPO and follow-on rounds at biotech and pharma companies, each with the amount, modality, most advanced phase, lead investors and a link to the press release or filing. Refreshed every week, built for CRO, CDMO and life-sciences sellers who need to know which sponsors just got money to spend.
65
Rounds tracked, last 60 days
$12.4B
Disclosed in total
$116.7M
Median disclosed round
Oct 25, 2026
Last updated
By Semir JahicCEO & Co-Founder, SalesmotionLast reviewed This period in short
- 65 rounds announced from Aug 26, 2026 to Oct 25, 2026, 65 with a disclosed amount, adding up to $12.4B.
- Small molecules led by number of rounds (18, $1.9B disclosed).
- 28 of 65 companies were preclinical or in Phase 1 at the time of the round: the stage at which outsourcing partners are still being chosen.
Public sources only: company press releases, SEC filings and, where no release was found, one reputable news report. Each row links to its source. The list is a selection of notable rounds, not a complete census.
Biotech financing rounds by modality
Number of rounds, then disclosed total. Modality of each company's most advanced program; "Other" means the source names none of these. Aug 26, 2026 to Oct 25, 2026.
Show the data as a table
| Modality | Rounds | Disclosed total |
|---|---|---|
| Small molecules | 18 | $1.9B |
| Antibodies and ADCs | 13 | $4.6B |
| RNA therapies | 8 | $1.1B |
| Other proteins and peptides | 3 | $529.2M |
| Gene therapies and gene editing | 3 | $424M |
| Cell therapies | 3 | $190M |
| Vaccines | 2 | $1.1B |
| Other | 11 | $2.1B |
| Platform / tools | 4 | $445M |
Rounds by most advanced phase
At the time of the announcement.
- Preclinical
- 20
- Phase 1
- 8
- Phase 2
- 13
- Phase 3
- 12
- Approved / commercial
- 3
- Not stated
- 9
Recent biotech and pharma financing rounds
Sort by date, company or amount. Filter by modality, phase and round size.
Showing 65 of 65 rounds
| Round | Modality | Phase | Lead investors | Source | |||
|---|---|---|---|---|---|---|---|
| Pathos AINew York, USA · Oncology (expanding to neurology)Scale Foundry AI platform; advance JSKN016 toward registrational studies, other assets | Series D+ | $237MSeries E at ~$3B post-money valuation | Other | Not stated | Bristol Myers Squibb | Company website press release | |
| Prana Therapies (via Bolt Biotherapeutics acquisition)Redwood City, USA · Inflammation (asthma, COPD, atopic dermatitis, EoE)Advance PRA-216 through multiple Phase 2 readouts; runway into 2028 | Follow-on / PIPE | $120MUpfront; Series D convertible preferred PIPE with reverse merger; up to $60M more via warrants | Antibodies and ADCs | Phase 2 | Not stated (investors incl. Deep Track, ADAR1, a16z, LYFE Capital) | SEC EDGAR 8-K Ex. 99.1 (company press release) | |
| Star TherapeuticsSouth San Francisco, USA · Diseases of significant unmet needMove preclinical programs into the clinic and add programs | Other | $200MPrivate financing, no series named; follows July 2026 sale of subsidiary Vega to Incyte | Antibodies and ADCs | Preclinical | OrbiMed, Janus Henderson Investors | BioSpace (syndicated Business Wire company press release) | |
| Lycia TherapeuticsSouth San Francisco, USA · Allergy (IgE / food allergy), Graves' diseaseClinical development of LCA-0061/0062 IgE portfolio and LCA-0321 | IPO | $317.5MUpsized; 17.64M shares at $18 (Nasdaq: LYCA) | Antibodies and ADCs | Phase 1 | Not stated (bookrunners: Jefferies, TD Cowen, Evercore ISI, Guggenheim) | SEC EDGAR 424B4 prospectus | |
| Warp SciencesSan Francisco, USA · Drug discovery services (AI/robotic chemistry CRO)Not specified; building AI- and robotics-enabled US chemistry labs | Other | $215MStealth launch; release names no series (media report it as Series A) | Platform / tools | Not stated | Lightspeed | Yahoo Finance (syndicated Business Wire company press release) | |
| Zai LabShanghai, China / Cambridge, USA · Oncology (ES-SCLC)Global development of DLL3 ADC zocilurtatug pelitecan | Follow-on / PIPE | $250MApprox.; PIPE of 11.34M ADSs at $22.04 | Antibodies and ADCs | Approved / commercial | TCGX | SEC EDGAR 8-K Ex. 99.1 (company press release) | |
| Arctic TherapeuticsReykjavik, Iceland · Neurology (dementia, HCCAA); autoimmuneAdvance AT-002 and AT-003 toward clinical development | Other | $21.5MOversubscribed, increased on demand; follows ~$31M Series A; round unnamed | Other | Phase 3 | Pekron, Sanos Group, Kaldbakur, Landvaettir | PR Newswire (company press release) | |
| Arcus BiosciencesHayward, USA · OncologyExpand and accelerate casdatifan clinical program; corporate purposes | Follow-on / PIPE | $250MUnderwritten offering, 14.29M shares at $17.50 | Small molecules | Phase 3 | Not stated (bookrunners: Jefferies, Leerink, TD Cowen, Evercore, Mizuho) | SEC EDGAR 424B5 prospectus supplement | |
| Alpha TeknovaHollister, USA · Life-science reagents (therapy, vaccine and diagnostics production)General corporate purposes, potentially repaying outstanding debt | Follow-on / PIPE | $40MUnderwritten offering, 8.0M shares at $5; plus 30-day option for 1.2M shares | Platform / tools | Not stated | Not stated (bookrunners: TD Cowen, William Blair) | SEC EDGAR 8-K Ex. 99.2 (company press release) | |
| Disc MedicineWatertown, USA · Hematology (EPP/XLP, iron homeostasis)R&D, potential bitopertin commercialization in EPP/XLP, working capital | Follow-on / PIPE | $450MUpsized underwritten offering, 6.0M shares at $75; plus 30-day option for 900k shares | Other | Not stated | Not stated (bookrunners: Jefferies, Leerink, Morgan Stanley, Cantor) | SEC EDGAR 8-K Ex. 99.2 (company press release) | |
| SurrozenSouth San Francisco, USA · Ophthalmology (DME, wet AMD)DUET Phase 1b/2a study of SZN-8141, start SZN-8143 clinical work; runway into 2029 | Follow-on / PIPE | $95.1MApprox.; second tranche of March 2025 private placement, triggered by SZN-8141 IND clearance | Other | Preclinical | Not stated | SEC EDGAR 8-K Ex. 99.1 (company press release) | |
| NouscomBasel, Switzerland · Oncology (cancer interception, Lynch syndrome)Registration-enabling trial of NOUS-209 in Lynch syndrome carriers | Series D+ | $135MEUR 120M (release states ~$135M); oversubscribed | Vaccines | Phase 2 | M Ventures, Revelation Partners | Company website press release | |
| TriGemX Bio (SPAC merger with TCGX Acquisition Corp.)New York / Palo Alto, USA · Neurology (migraine)Phase 3 migraine trials, NDA, prevention trial, launch readiness | Follow-on / PIPE | $160MPIPE at $10/share with SPAC deal; ~$246M gross incl. trust if no redemptions | Other | Phase 3 | Not stated (investors incl. TCGX, Viking, ADAR1, BVF, Samsara) | SEC EDGAR 8-K Ex. 99.1 (joint press release) | |
| Estuary BiotherapeuticsMenlo Park / Newton, USA · Nephrology (ADPKD)Take AAV programs EST-201 and EST-101 to clinical POC; kidney platform | Series A | $93M$103M total committed incl. $10M seed | Gene therapies and gene editing | Preclinical | RA Capital Management | Company website press release | |
| MicrobioticaCambridge, UK · Inflammatory bowel disease (ulcerative colitis)Advance live biotherapeutic MB310 into Phase 2 in ulcerative colitis | Series C | $48MGBP 36M first close | Other | Phase 1 | British Business Bank | Company website press release | |
| City TherapeuticsCambridge, USA · Thromboembolic disease; Stargardt; anemiaCITY-FXI, CITY-RBP4, CITY-TFR2 and RNAi platform | IPO | $200MUpsized; 11.1M shares at $18 (Nasdaq: CTY), before underwriter option | RNA therapies | Phase 1 | Not stated (bookrunners: Goldman Sachs, Jefferies, Stifel, Oppenheimer) | SEC EDGAR 424B4 prospectus | |
| First Tracks BiotherapeuticsSan Diego, USA · Autoimmune / inflammatory (celiac, EoE)General corporate purposes incl. clinical development of ANB033 | Follow-on / PIPE | $200MPrivate placement, 6.1M shares at $32.75 | Antibodies and ADCs | Not stated | Not stated (investors incl. Affinity, First Light, Sirenia, TCGX, Vestal Point) | SEC EDGAR 8-K Ex. 99.1 (company press release) | |
| OMass TherapeuticsOxford, UK · Endocrinology / immunology (CAH, Cushing's, lupus)Phase 2 of MC2R antagonist OMS1620; first clinical data for SLC15A4 inhibitor | Series C | $310MGBP 230M; oversubscribed | Small molecules | Phase 2 | Bain Capital Life Sciences, Forbion, Novo Holdings | Company website press release | |
| Altay TherapeuticsSan Carlos, USA · Neuromuscular (FSHD)Take oral DUX4 inhibitor DX5057 through Phase 1 and Phase 2 POC | Series A | $37M | Small molecules | Preclinical | Sound Bioventures, HealthCap | BioSpace (syndicated Business Wire company press release) | |
| Iambic TherapeuticsSan Diego, USA · Oncology (HER2-altered solid tumors)Advance IAM1363 toward Phase 2/3, IAM217, IAM-C1, AI platform | IPO | $150M9.375M shares at $16 (Nasdaq: IAM) | Small molecules | Phase 1 | Not stated (bookrunners: J.P. Morgan, Jefferies, BofA, Citigroup) | SEC EDGAR 424B4 prospectus | |
| Prolific MachinesEmeryville, USA · Biomanufacturing (optogenetic bioprocessing)Scale optogenetic biomanufacturing platform, pharma programs, team | Series B | $50MSeries B2 initial closing | Platform / tools | Not stated | Atoms & Bits, Nant Capital | BioSpace (syndicated PR Newswire company press release) | |
| Verastem OncologyNeedham, USA · Oncology (RAS/MAPK cancers)Clinical development of VS-7375; working capital | Follow-on / PIPE | $250MUnderwritten offering: 30.9M shares at $8 plus pre-funded warrants | Small molecules | Approved / commercial | Not stated (bookrunners: Jefferies, Guggenheim, Cantor) | SEC EDGAR 424B5 prospectus supplement | |
| Souffle TherapeuticsBoston, USA · Neuromuscular / cardiovascular (FSHD, HFrEF)Move three extra-hepatic oligonucleotide programs into first clinical studies | Series B | $135MOversubscribed | RNA therapies | Preclinical | Juvia Group | BioSpace (syndicated Business Wire company press release) | |
| Undecimal BioCambridge, UK / Tel Aviv, Israel · Renovascular diseaseBuild DELiveri siRNA-delivery platform, renovascular programs, team | Seed | $18MOversubscribed | RNA therapies | Not stated | 4BIO Capital, IQ Capital | Cambridge Network (company press release posted by its PR agency) | |
| Velaris Therapeutics (merging into Alaunos Therapeutics)Waltham, USA · Pulmonary hypertensionProof-of-concept data for VLR199/VLR360, first filings for VLR247/VLR258; runway into 2029 | Follow-on / PIPE | $350MApprox.; Series C convertible preferred private placement alongside reverse merger | Other proteins and peptides | Preclinical | Fairmount | SEC EDGAR 8-K Ex. 99.2 (company press release) | |
| ADC TherapeuticsLausanne, Switzerland · Oncology (B-cell lymphoma)ZYNLONTA Phase 3 studies in DLBCL and MZL; balance sheet | Follow-on / PIPE | $86.6MPIPE: common at $1.42 and pre-funded warrants | Antibodies and ADCs | Approved / commercial | Bain Capital Life Sciences (new), with Redmile, TCGX, Nantahala | SEC EDGAR 8-K Ex. 99.1 (company press release) | |
| Atrium TherapeuticsSan Diego, USA · Cardiology (genetic cardiomyopathies)Develop two lead siRNA candidates; runway through 2028 | Follow-on / PIPE | $50MApprox.; private placement of common and pre-funded warrants priced at-the-market | RNA therapies | Phase 2 | Not stated (investors incl. Sirenia, Aberdeen, Sessa, Casdin) | SEC EDGAR 8-K Ex. 99.1 (company press release) | |
| Retension PharmaceuticalsFalls Church, USA · Cardiovascular (hypertension)Complete Phase 2b and prepare Phase 3 of RTN-001 in hypertension | IPO | $45M3.75M shares at $12 (Nasdaq: RTSN) | Small molecules | Phase 2 | Not stated (underwriters: Leerink, Guggenheim, Oppenheimer, Titan) | SEC EDGAR 424B4 prospectus | |
| TRex BioSouth San Francisco, USA · Immunology (atopic dermatitis)Phase 2 of TNFR2 agonist TRB-061 in AD and alopecia; TRB-071 Phase 1 | IPO | $116.7M8.33M shares at $14 (Nasdaq) | Other proteins and peptides | Phase 1 | Not stated (bookrunners: J.P. Morgan, Evercore ISI, Cantor, Stifel) | SEC EDGAR 424B4 prospectus | |
| Matchpoint TherapeuticsWatertown, USA · Autoimmune / inflammatoryTake oral T cell modulator MPT-062 to clinical proof-of-concept; pipeline | Series B | $150M | Small molecules | Preclinical | Nextech Invest, Norwest | BioSpace (syndicated GlobeNewswire company press release) | |
| KymaTheraSan Diego, USA · Oncology (HR+/HER2- breast); vascular malformationsAdvance PI3Ka inhibitor K-1728 through initial clinical proof-of-concept | Series B | $80M | Small molecules | Preclinical | Alta Partners | PR Newswire (company press release) | |
| RougeTxNaarden, Netherlands · Vascular (hereditary hemorrhagic telangiectasia)Advance oral RTX-001 toward first-in-human trials in HHT | Series A | $58M | Small molecules | Preclinical | BioGeneration Ventures, Angelini Ventures, Kurma Partners | Company website press release | |
| VaxcyteSan Carlos, USA · Infectious disease (pneumococcal)VAX-31 adult/pediatric development, manufacturing scale-up, US launch preparation | Follow-on / PIPE | $1BUSD 500M common + pre-funded warrants at USD 64 + USD 500M 1.50% convertible notes due 2032 (concurrent offerings, one release); USD 1.15B at closing incl. options | Vaccines | Phase 3 | Not stated (bookrunners: Jefferies, Leerink, BofA, Goldman Sachs, Evercore) | Company investor site press release | |
| Spyre TherapeuticsWaltham, USA · Immunology (IBD, rheumatology, dermatology)Advance GI, rheumatology, dermatology programs incl. Phase 3 readiness | Follow-on / PIPE | $350MUnderwritten offering, 4.12M shares at $85; $402.5M if option exercised | Antibodies and ADCs | Phase 2 | Not stated (bookrunners: Jefferies, TD Cowen, Leerink, Stifel) | SEC EDGAR 424B5 prospectus supplement | |
| TriGemX Bio (formerly Kallyope)New York, USA · Neurology (acute migraine)Advance clinical development of elismetrep (oral TRPM8 blocker) | Other | $94MPrivate financing, no series named; separate $160M SPAC PIPE announced 2026-10-19 (own row) | Other | Phase 3 | The Column Group, TCGX, Viking Global Investors | BioSpace (syndicated Business Wire company press release) | |
| AnaCardioStockholm, Sweden · Cardiovascular (HFrEF)Fully fund 400-patient GOAL-HF2 Phase 2b of AC01 | Series B | $70.9MEUR 62.5M; USD approx at ~1.13 USD/EUR (no rate in release) | Small molecules | Phase 2 | Novo Holdings, Ljungstrom family office | Company website press release | |
| ai3BioPittsburgh / Watertown, USA · Autoimmune / inflammatoryIND-enabling work on LNP-mRNA and antibody Th17-depletion platforms | Series A | $48M | Other | Preclinical | UPMC Enterprises, Ziff Capital Partners | BioPharma Dive (news) | |
| Breye TherapeuticsCopenhagen, Denmark · Ophthalmology (diabetic retinopathy)Phase 2 of danegaptide in NPDR; iAMD and glaucoma pipeline | Series A | $76.5MEUR 67.5M; USD approx at ~1.13 USD/EUR (no rate in release) | Small molecules | Phase 1 | Mission BioCapital, Novo Holdings | Company website press release | |
| Link Cell TherapiesAustin / South San Francisco, USA · Oncology (clear cell RCC, colorectal)Advance logic-gated CAR-T programs, colorectal cancer first-in-human trial in 2027 | Series A | $30MSeries A extension; total Series A now USD 90M (was USD 60M) | Cell therapies | Phase 1 | Johnson & Johnson Innovation - JJDC (original lead); new: BMS, Kyowa Kirin, others | Company website press release | |
| Summit TherapeuticsMiami, USA · Oncology (NSCLC)Not specified; company retains broad discretion over proceeds | Follow-on / PIPE | $2BStrategic equity investment by AstraZeneca in convertible preferred stock ($18.36/share common-equivalent) | Antibodies and ADCs | Phase 3 | AstraZeneca | SEC EDGAR 8-K Ex. 99.1 (company press release) | |
| ADARx PharmaceuticalsSan Diego, USA · Complement-mediated diseases, HAE, thrombosisAdvance siRNA programs agazisiran, onvuzosiran, ADX-626/077/199 and pipeline expansion | IPO | $446.3MBase IPO 26.25M shares at USD 17 (424B4: USD 446.25M); plus concurrent AbbVie private placement capped at USD 100M; greenshoe exercised 1 Oct (outside window) | RNA therapies | Phase 3 | Not stated (underwritten IPO); AbbVie concurrent placement | SEC EDGAR 424B4 prospectus | |
| BigHat BiosciencesSan Mateo, USA · Oncology (GI cancers)Advance BHB810 ADC and BHB299 T-cell engager; expand AI protein-design data platform | Series C | $75M | Antibodies and ADCs | Phase 1 | DFJ Growth and Premji Invest (co-leads) | BigHat newsroom (company press release) | |
| Kasvu TherapeuticsHelsinki, Finland · CNS (depression)IND/CTA-enabling studies and Phase 1/1b of TrkB potentiator KTX-0141 | Series A | $34.4MEUR 30M; approx. conversion, release gives no USD figure | Small molecules | Preclinical | Hadean Ventures | Kasvu Therapeutics website (company press release) | |
| Viking TherapeuticsSan Diego, USA · Obesity / metabolicClinical development and commercialization of VK2735; VK3019; general corporate purposes | Follow-on / PIPE | $500MUSD 275M common stock at USD 35 + USD 225M 2.00% convertible notes due 2032 (one release); upsized from USD 400M | Other | Phase 3 | Not stated (underwritten offering) | PR Newswire (company press release) | |
| Basecamp ResearchLondon, UK · Oncology and autoimmune diseaseTrain new EDEN AI models, advance in vivo pipeline to clinic, expand pharma partnerships | Series C | $140MOversubscribed | Platform / tools | Preclinical | S32 | PR Newswire (company press release, corrected) | |
| EnvedaBoulder, USA · Inflammation and metabolic diseaseMove ENV-294 and ENV-308 to later-stage trials, ENV-6946 mid-phase, scale PRISM AI platform | Series D+ | $311MSeries E | Other | Phase 2 | Catalio Capital Management | Enveda newsroom (company press release) | |
| Electra TherapeuticsSouth San Francisco, USA · Immunology (sHLH) and oncologyIpsoprubart registrational sHLH trial, BLA and launch prep; ELA822 Phase 1 | IPO | $350MUpsized; 23,333,334 sh at USD 15; underwriters' option for 3.5M more shares | Antibodies and ADCs | Phase 3 | Not stated (underwritten IPO) | SEC EDGAR 424B4 prospectus | |
| Marea Therapeutics (via Lisata Therapeutics acquisition)USA · Cardioendocrine (sHTG, acromegaly)Complete MAR001 Phase 2b in sHTG and MAR002 Phase 2 in acromegaly; runway into 2028 | Follow-on / PIPE | $225MApprox. USD 225M gross concurrent private placement of Lisata Series C convertible preferred | Antibodies and ADCs | Phase 2 | Not stated; investors incl. RA Capital, Forbion, Third Rock, Alpha Wave, Perceptive | SEC EDGAR 8-K Ex. 99.1 (Lisata press release) | |
| North Immunology (via Aethlon Medical merger)Austin, USA · Immunology (atopic dermatitis)Advance NOR-101 (IL-13/IL-18 bispecific) into clinic; runway into 2H 2028 | Follow-on / PIPE | $180MApprox. USD 180M gross, includes ~USD 34M conversion of North convertible notes | Antibodies and ADCs | Preclinical | Not stated; investors incl. Bain Capital Life Sciences, Janus Henderson, Deep Track | SEC EDGAR 8-K Ex. 99.1 (Aethlon / North Immunology press release) | |
| Circle PharmaSouth San Francisco, USA · Oncology (ER+ breast cancer)Take macrocyclic cyclin D1 inhibitor CID-165 into clinic (Q1 2027); cyclin pipeline | Series D+ | $92.5MSeries E, oversubscribed | Other | Not stated | The Column Group | Circle Pharma newsroom (company press release) | |
| Sling TherapeuticsAnn Arbor, USA · Thyroid eye diseasePhase 3 ORBIT trial of oral linsitinib and commercial readiness | Series C | $123M | Small molecules | Phase 3 | Forbion | Sling Therapeutics newsroom (company press release) | |
| RegCellEmeryville, USA · Autoimmune diseaseIND for Treg reprogramming platform, Phase 2 in second indication, next-gen platform | Series A | $44MUSD 44M Series A equity; plus ~USD 22M (JPY 3.4B) non-dilutive AMED grant; USD 66M total | Cell therapies | Not stated | Playground Global | BioSpace (Business Wire company press release republished) | |
| Caspian TherapeuticsSan Diego, USA · Diabetes / cardiometabolicIND-enabling work and early clinical proof-of-concept for menin inhibitor KO-7246 | Other | $50MLaunch financing (Kura Oncology spinout; Kura keeps about half) | Small molecules | Preclinical | BVF Partners | Caspian Therapeutics website (company press release) | |
| Encoded TherapeuticsSouth San Francisco, USA · Neurology (Dravet syndrome)ETX101 pivotal and expansion studies, scale GMP manufacturing, ETX301 toward 2027 IND | Series D+ | $275MSeries F | Gene therapies and gene editing | Phase 2 | GV and an undisclosed healthcare fund (co-leads) | Encoded newsroom (company press release) | |
| Solstice OncologyCambridge, MA, USA · Oncology (neoadjuvant MSS colon cancer)Phase 2 trial of porustobart with pembrolizumab, opening Q4 2026 | Series A | $225MLaunch round | Antibodies and ADCs | Phase 2 | RA Capital Management | PR Newswire (Harbour BioMed / Solstice Oncology press release) | |
| Tectora TherapeuticsNot stated · Immunology and inflammationAdvance SDGR-4594 and SDGR-8139 oral programs to clinical candidates | Series A | $55MLaunch round; Schrodinger co-founded and contributed two programs | Small molecules | Preclinical | NEA and RA Capital Management | Schrodinger investor relations (press release) | |
| TwoStep TherapeuticsSan Carlos, USA · Oncology (solid tumors)Phase 1 of peptide-drug conjugate TS-104 (IND cleared), radioligand program, new conjugates | Series A | $62.5MOversubscribed | Other proteins and peptides | Preclinical | Insight Partners and Medical Excellence Capital; co-leads M Ventures, Pfizer Ventures | TwoStep newsroom (company press release) | |
| BrainChild BioSeattle, USA · Oncology (pediatric CNS tumors, DIPG)Registrational Phase 2 ILLUMINATE trial of BCB-276 in DIPG; BCB-214 in glioblastoma | Series A | $116M | Cell therapies | Phase 2 | Undisclosed private family fund and foundation | BioSpace (GlobeNewswire company press release republished) | |
| Cloverleaf BioNew Haven, USA · Oncology (HCC, colorectal cancer)Inhibitory tRNA for HCC into early clinic; antibody-tRNA conjugate for CRC preclinical | Seed | $33MUpsized and oversubscribed | RNA therapies | Preclinical | 4BIO Capital | BioSpace (GlobeNewswire company press release republished) | |
| Moonwalk BiosciencesSouth San Francisco, USA · Obesity / cardiometabolicTake adipose-targeted siRNA MW101 to first-in-human in late 2027; expand pipeline | Series B | $70MOversubscribed | RNA therapies | Preclinical | Alpha Wave and YK Bioventures (co-leads) | BioSpace (Business Wire company press release republished) | |
| NeuShen TherapeuticsShanghai, China · CNS (schizophrenia, AD agitation, epilepsy)Expand CNS pipeline and advance clinical programs in global trials | Series B | $80MRelease says 'more than USD 80M' | Small molecules | Phase 2 | Not stated; investors incl. B Capital, Legend Capital, Matrix Partners China, Lilly Asia Ventures | NeuShen newsroom (company press release) | |
| Superluminal MedicinesBoston, USA · Rare genetic and hypothalamic obesityStart Phase 1 of biased MC4R agonist by end 2026; expand GPCR pipeline | Series B | $60MOversubscribed | Small molecules | Preclinical | BVF Partners | PR Newswire (company press release) | |
| Typewriter TherapeuticsCambridge, MA, USA · Oncology / autoimmune (in vivo CAR T), genetic liver diseaseNominate first in vivo CAR T candidate using all-RNA R2 gene insertion | Series A | $56MEmerged from stealth | Gene therapies and gene editing | Preclinical | AN Venture Partners and RA Capital Management | PR Newswire (company press release) | |
| Kazia TherapeuticsSydney, Australia · Oncology (glioblastoma, breast cancer)Paxalisib clinical development incl. breast cancer studies; working capital | Follow-on / PIPE | $40MAbout USD 40M upfront; up to USD 120M total if Series A/B warrants are fully exercised | Small molecules | Phase 3 | Bookrunners: Leerink Partners, Guggenheim Securities | PR Newswire (company press release) | |
| AusperBio TherapeuticsSan Francisco, USA · Chronic hepatitis BAHB-137 Phase 3 and commercial readiness; advance AHB-171 siRNA and combinations | Series C | $120M | RNA therapies | Phase 3 | Undisclosed strategic investor; RA Capital new investor | PR Newswire (company press release) |
Amounts in US dollars as stated in the source; other currencies converted at the rate the source gives, or shown next to the amount. Phase and modality follow the company's own description.
Why a funding round is a sales trigger for CROs and CDMOs
For a contract research or manufacturing partner, a financing round is one of the clearest public signs that a sponsor is about to buy outside work. It names a budget, a program and a timeline at the same time. The round itself is not the opportunity; the studies and the manufacturing it pays for are. The full playbook is in how to use a funding round as a sales trigger.
The money has a named job
A release almost always says what the round pays for: IND-enabling studies, a first-in-human trial, a Phase 2 readout, a manufacturing scale-up. That sentence is the brief for a CRO, CDMO or lab, and the first line of the message.
Outsourcing decisions follow within months
Small sponsors run lean and outsource most of the work. After a raise they hire the first clinical operations, CMC or regulatory lead, and that person builds the vendor shortlist. Reach them while the list is still open.
Phase decides the buyer and the window
A preclinical or Phase 1 company is still choosing partners. By Phase 3 the main vendors are usually set, and the opportunity is a specialty service or a second source, not the core study.
One round predicts the next events
A financed sponsor tends to produce a run of follow-on signals: trial registrations, site activations, new hires, partnerships. Tracking the account after the raise matters as much as catching the raise.
“really, we don't do much with phase threes at that point. They have a CRO locked in.”
Anonymised buyer
Business development, CRO
Turn a round into a first message
- Check fit first: modality and phase decide whether your service is relevant at all.
- Read the use of funds and the program it names. That is your reason to write.
- Find the person who will scope the work: clinical operations, CMC, regulatory or the CSO at a small sponsor.
- Write within days. Lead with the program and the next milestone, not with congratulations.
- Keep tracking the account: trial registrations, hires and partnerships follow the raise.
Funding Round Sales Trigger: A How-To Guide for Rev TeamsLearn how to use the funding round sales trigger to generate pipeline. This playbook covers signal detection, outreach timing, and messaging that works.Biotech Buying Signals: Clinical Trial and FDA TriggersThe biotech buying signals that predict purchase timing: phase transitions, readouts, PDUFA dates, FDA designations, funding, partnerships and CCO hires.Biotech Companies by Modality: 2,298 Sponsors Counted2,298 clinical-stage biotech sponsors counted by modality and phase: 540 small molecule, 434 antibody, 172 cell and 164 gene therapy, with company lists.
Get the round soon after it is announced, for the sponsors you sell to
This page is a weekly sample. Salesmotion for Life Sciences watches every sponsor in your book for financings, trial starts, phase changes, readouts and FDA events, finds new sponsors by modality, phase and therapeutic area, and drafts outreach anchored to the event. A single seat that monitors a list you bring starts at $85/mo.
How this tracker is built
- Window: rounds announced from Aug 26, 2026 to Oct 25, 2026. Older rows drop off at each weekly refresh.
- Sources: the company's press release (PR Newswire, Business Wire, GlobeNewswire or its own newsroom, or a dated verbatim copy of it on BioSpace or Yahoo Finance) or an SEC filing on EDGAR. Where neither was found, one named news report. The date is the date on the source.
- Scope: drug developers first, plus a few platform and tools companies. Notable rounds only; small, undisclosed or regional rounds may be missing.
- Amounts are gross proceeds at announcement or pricing, before any later option exercise. Convertible notes count only when the release states their amount as part of the financing (for example, concurrent stock and note offerings announced together).
- Modality and phase describe the most advanced program at the time of the round, as the company states it.
- No Salesmotion customer data or product data is used on this page.
Spotted an error or a missing round? Email hi@salesmotion.io with the source link.
Biotech funding FAQ
Where can I find recent biotech funding news?
The primary sources are company press releases on Business Wire, GlobeNewswire and PR Newswire, and SEC filings on EDGAR (8-K, S-1 and 424B4) for IPOs and private placements. Trade outlets such as Fierce Biotech, Endpoints News and BioSpace publish round-ups. This tracker lists notable rounds of the last 60 days with a source link for each one, and is refreshed weekly.
Why does a biotech funding round matter to CROs and CDMOs?
A financing round is the moment a sponsor turns a plan into spend. The release usually names what the money is for, such as an IND-enabling package, a first-in-human study or a Phase 2 trial, and that work is often outsourced. Outreach that arrives while the sponsor is still choosing partners has a chance. By Phase 3 the CRO is usually locked in. See the funding round sales trigger playbook.
How soon after a biotech raises money should a vendor reach out?
Within days, not months. The weeks after a round are when a sponsor builds its plan, hires its first clinical, CMC or regulatory leads and shortlists partners. Open with the program and the use of funds named in the release, not with congratulations, and send it to the person who will scope the work. The biotech buying signals guide covers the other triggers that follow a raise.
Which biotech modalities are raising the most money?
The chart on this page counts the rounds of the last 60 days by the modality of each company's most advanced program, with the disclosed dollar total. For how many clinical-stage sponsors work in each modality overall, see biotech companies by modality. Modality matters for vendors because it decides whether an offer fits at all.
How do I get alerts when a biotech in my territory raises money?
Track the sponsors you sell to and get an alert when a financing, trial start, phase change or regulatory event appears in a public source. Salesmotion does this for a list you bring from $85/mo for 100 accounts, and Salesmotion for Life Sciences adds sponsor discovery by modality, phase and therapeutic area.
Know which sponsors just got money to spend.
Salesmotion tracks financings, trials and regulatory events for the sponsors you sell to and drafts the outreach. From $85/mo for 100 accounts. Book a 30-minute demo or try the interactive demo first.